Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
30 studies found for:    " December 11, 2010":" January 10, 2011"[FIRST-RECEIVED-DATE]AND HIV[CONDITION]
Show Display Options
Rank Status Study
21 Active, not recruiting A Trial With TMC278-TIDP6-C222 for Continued TMC278 Access in Patients Infected With Human Immunodeficiency Virus-1
Condition: HIV-1 Infection
Intervention: Drug: Rilpivirine
22 Withdrawn A Study to Investigate the Recovery, Excretion, and Pharmacokinetics of 14C-GSK2248761 Administered as an Oral Suspension to Healthy Adult Subjects
Condition: Infection, Human Immunodeficiency Virus
Intervention: Drug: 200mg [14C]- GSK2248761
23 Terminated Biomarkers in Blood Samples From Patients With HIV Infection and Stage III or Stage IV Hodgkin Lymphoma Undergoing Chemotherapy
Conditions: Lymphoma;   Nonneoplastic Condition
Interventions: Genetic: DNA analysis;   Genetic: RNA analysis;   Other: laboratory biomarker analysis
24 Active, not recruiting TMC114IFD3001 - Study Providing Continued Access to Treatment With Darunavir (DRV)/Ritonavir (Rtv) for Adults Coming From Any of the Three Ongoing Tibotec-Sponsored Studies With DRV
Condition: HIV-1 Infections
Interventions: Drug: Darunavir;   Drug: ritonavir
25 Completed Safety and Immunogenicity Study of a Candidate Tuberculosis Vaccine in Human Immunodeficiency Virus (HIV)-Positive Adults
Condition: Tuberculosis
Interventions: Biological: GSK's investigational vaccine 692342;   Biological: Physiological saline
26 Recruiting A Trial of Observed Long-acting, Anti-HIV Treatment With a Monoclonal CCR5 Antibody (PRO 140) as an Adjunct to a New, Optimized, Oral Antiretroviral Regimen in HIV-infected Injection Drug Users With Viral Rebound and Documented Poor Adherence
Condition: HIV
Interventions: Drug: PRO 140;   Drug: Placebo
27 Completed
Has Results
Effects of Switching Efavirenz to Raltegravir on Vascular Function and Bone Markers in HIV-infected Patients
Condition: HIV
Interventions: Drug: Tenofovir/emtricitabine;   Drug: Tenofovir/emtricitabine/efavirenz;   Drug: Raltegravir
28 Completed A Phase I, Open-label Trial to Explore the Pharmacokinetics, Safety and Tolerability of TMC278 (Rilpivirine) 25 mg Once Daily Following a 2-week Period Receiving Efavirenz, in Healthy Male and Female Volunteers
Condition: HIV
Interventions: Drug: TMC278;   Drug: Efavirenz
29 Completed Preparing for International Prevention Trials Involving HIV-Infected Individuals in Care Settings
Condition: HIV
30 Enrolling by invitation Effects of Maraviroc (MVC) on HIV-related Kaposi's Sarcoma (KS)
Condition: Kaposi's Sarcoma
Intervention: Drug: Maraviroc

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-30) Next Page   
Indicates status has not been verified in more than two years